National Tribune
Sunday, 22 November 2026
Health

Alzheimer’s breakthrough exposes a hidden flaw in the brain’s cleanup system

Alzheimer’s breakthrough exposes a hidden flaw in the brain’s cleanup system

- Date:

- November 21, 2026

- Source:

- University of Virginia Health System

- Summary:

- Scientists have identified a gene that helps the brain’s immune cells contain harmful plaques linked to Alzheimer’s, potentially revealing a new way to fight the disease. When the gene malfunctioned in mice, toxic buildup accelerated and cognitive abilities declined, raising hopes that restoring its function could help protect the brain.

- Share:

A gene that helps the brain contain harmful protein buildup may play a crucial role in Alzheimer's disease. Researchers at UVA Health have discovered that when this gene stops functioning properly, the brain's natural defenses become less effective, allowing toxic plaques to accumulate more rapidly. The findings could point toward new ways to detect, treat, or potentially prevent the disease.

The research, led by John Lukens, PhD, focused on a gene called CASS4, which previous studies had repeatedly linked to an increased risk of Alzheimer's. Until now, however, scientists knew little about what the gene actually does. The team discovered that CASS4 helps regulate microglia, specialized immune cells that act as the brain's cleanup and defense system. When the gene's activity was disrupted, these cells struggled to respond to harmful plaques. They also became much less effective at containing and compacting the toxic material, allowing the plaques to expand and spread more aggressively.

"These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer's disease," said Lukens, director of UVA's Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases. "Our work further suggests that defective CASS4 activity may serve as an early-onset biomarker to detect Alzheimer's and that therapeutic strategies which boost its function may offer a much-needed approach to treat this devastating brain disease."

How the Brain's Cleanup System Protects Against Alzheimer's

More than 6 million Americans are living with Alzheimer's, a progressive disease that gradually damages memory and thinking abilities. As the condition advances, people can lose the ability to recognize even their closest family members, including their own children. Alzheimer's is the sixth-leading cause of death in the United States, according to the figures cited by the researchers.

Two major changes in the brain are associated with the disease. One is the accumulation of amyloid-beta plaques, sticky deposits of protein that collect between nerve cells. The other is the formation of twisted tangles of a protein called tau. Both are hallmarks of Alzheimer's, but growing evidence suggests that the brain's immune system, particularly its microglia, also plays an important role in how the disease develops.

Microglia normally help protect the brain by responding to threats and managing harmful material. When amyloid-beta plaques appear, these immune cells can surround them with protective barriers and compress the deposits into smaller, more tightly packed structures. This containment process helps limit the damage the plaques can cause to surrounding brain tissue.

The UVA researchers found that CASS4 is important for maintaining this protective response. When the gene was disrupted in laboratory mice, microglia became less capable of controlling amyloid-beta plaques. As a result, the plaques accumulated more rapidly, nearby nerve cells called neurons suffered damage, and the animals experienced worsening cognitive function.

A Little-Known Alzheimer's Gene Reveals Its Role

"Despite CASS4 being an Alzheimer's risk gene, really nothing is known about what this gene does or how it affects the brain during disease. Our lab sought to address this major knowledge gap with this paper," said Addie Walsh, UVA physiology graduate student and first author of the paper. "These are important findings because they give us new insight into how this understudied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology."

The researchers also discovered that losing CASS4 set off a series of changes in the activity of other genes. These widespread effects could have implications beyond Alzheimer's, potentially helping explain biological processes involved in other neurodegenerative diseases, which progressively damage nerve cells.

One of the most significant findings was where CASS4 appears to exert its influence. Scientists had previously suspected that the gene contributed to Alzheimer's primarily through its effects on neurons, the cells responsible for transmitting information throughout the brain. Instead, the new research indicates that its main role is in the immune system.

That distinction could be important for developing future treatments. Rather than focusing exclusively on neurons or the proteins that accumulate in Alzheimer's, researchers may be able to strengthen the immune cells that help protect the brain from those deposits. The UVA team believes that increasing CASS4 activity or improving microglial function could eventually offer ways to slow or prevent the disease.

A Potential New Target for Alzheimer's Treatments

"We are now actively exploring potential roles for CASS4 in multiple other neurodegenerative disorders and developing novel strategies to therapeutically target it," said Lukens, of the Department of Neuroscience at the University of Virginia School of Medicine. "Many in the field initially presumed that CASS4 was likely functioning in neurons to influence Alzheimer's. Our findings shift this paradigm by proving that CASS4 predominantly acts through the immune system. This is particularly exciting, as it has only been in recent years that immune-targeting strategies have been considered for the treatment of neurodegenerative diseases, and this remains an untapped therapeutic avenue with tremendous potential."

The findings suggest that the brain's immune defenses may offer an important opportunity for future Alzheimer's therapies. They also raise the possibility that defective CASS4 activity could eventually serve as an early warning sign of the disease, potentially helping doctors identify people at risk before more serious symptoms develop.

However, these possibilities remain to be tested. The experiments showing increased plaque buildup, neuronal damage, and cognitive decline were conducted in mice. Further research will be needed to determine whether targeting CASS4 can produce similar protective effects in humans.

The work is part of a broader effort at UVA to translate laboratory discoveries into treatments for serious diseases. Lukens leads the Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, which operates within UVA's newly established Paul and Diane Manning Institute of Biotechnology. The institute was created to accelerate the development of medicines and other therapies for complex medical conditions using advances from UVA's biomedical research programs.

Lukens is also a member of UVA's Center for Brain Immunology and Glia (BIG Center), which studies the roles of immune cells and other supporting cells in brain health and disease.

Walsh, meanwhile, is preparing to continue her research into the brain's immune system in a new position.

"I will be heading to Boston at the end of the year to start my postdoctoral research with the Neurodegeneration Team at the pharmaceutical company Novartis," she said. "I am looking forward to continuing to study microglia in neurodegeneration."

Alzheimer's Gene Discovery Published in Scientific Journal

The research was published in the Journal of Experimental Medicine. The authors are Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo and Lukens. The researchers reported having no financial interest in the work.

Among the contributors is Davis, a fourth-year biology student at UVA, who says participating in scientific research has helped shape his approach to problem-solving and his plans for a career in medicine.

"I think that undergraduate research develops a kind of critical thinking that is difficult to cultivate inside a classroom," he said. "My experience with research has taught me to approach questions systematically and never assume there will be a clear answer. As I prepare to apply to medical school, I know these experiences will shape how I approach clinical care and the broader field of science."

Funding came from the National Institutes of Health's National Institute on Aging through grants R01AG071996, R01AG087406, RF1AG078684 and R01AG086344. Additional support was provided by the Cure Alzheimer's Fund, the Owens Family Foundation, the Harrison Family Foundation, the Rick Sharp Foundation, and the Steven A. Newman AD Award.

Story Source:

Materials provided by University of Virginia Health System. Note: Content may be edited for style and length.

Journal Reference:

- Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, John R. Lukens. Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis. Journal of Experimental Medicine, 2026; 223 (12) DOI: 10.1084/jem.20260104

Cite This Page:

Originally reported by ScienceDaily.